Nicotinamide phosphoribosyltransferase is a key metabolic enzyme that is a potential target for oncology. Utilizing publicly available crystal structures of NAMPT and in silico docking of our internal compound library, a NAMPT inhibitor, 1, obtained from a phenotypic screening effort was replaced with a more synthetically tractable scaffold. This compound then provided an excellent foundation for further optimization using crystallography driven structure based drug design. From this approach, two key motifs were identified, the (S,S) cyclopropyl carboxamide and the (S)-1-N-phenylethylamide that endowed compounds with excellent cell based potency. As exemplified by compound 27e such compounds could be useful tools to explore NAMPT biology in vivo.

烟酰胺磷酸核糖基转移酶是关键的代谢酶，是肿瘤学的潜在靶标。利用NAMPT的公开晶体结构和我们内部化合物库的计算机对接，将从表型筛选工作中获得的NAMPT抑制剂1替换为可合成的更易于操作的支架。然后，该化合物为基于晶体学驱动的基于药物设计的结构的进一步优化奠定了良好的基础。通过这种方法，确定了两个关键的基序，（S，S）环丙基羧酰胺和（S）-1- N-苯基乙基酰胺赋予化合物基于细胞的优异效能。如化合物27e所示这些化合物可能是探索体内NAMPT生物学的有用工具。